HeartSciences Q3 no revenue, $1.9M cash; progresses MyoVista FDA clearance, adopts equity plan

HeartSciences Inc.

No meaningful Q3 FY2023 revenues; cash and equivalents $1.9M as of Jan 31, 2023.
MyoVista pivotal validation study enrollment progressing for FDA De Novo resubmission; additional enrichment patients enrolled.
Board adopted 2023 Equity Incentive Plan, subject to stockholder approval, covering employees, directors, and consultants.
Collaboration with Rutgers University for AI-based ECG algorithms; patent portfolio now 40 (9 U.S., 31 international).
Appointed microcap veteran David R. Wells to Board of Directors.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

HeartSciences Inc. reported the fiscal 2023 third quarter ended January 31, 2023 results: revenue no meaningful revenues.

Period: the fiscal 2023 third quarter ended January 31, 2023
Revenue: no meaningful revenues
Result: reported results

Exact text from the filing

Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company") , a medical technology company focused on saving lives by making an ECG (also known as an EKG) a more valuable screening tool through the use of Artificial Intelligence (AI), today provided a business update and reported financial results for the fiscal 2023 third quarter ended January 31, 2023.

View on SEC.gov

Browse all earnings releases →

HeartSciences Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-008500

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.